Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation-Reference-Cited by-同舟云学术

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation

Published:2017-03-14 Issue:4 Volume:7 Page:e00671
ISSN:2162-3279
Container-title:Brain and Behavior
language:en
Short-container-title:Brain Behav

Author:

González-Suarez Inés¹^ORCID,Rodríguez de Antonio Luis²,Orviz Aida¹,Moreno-García Sara³,Valle-Arcos María D.³,Matias-Guiu Jordi A.¹,Valencia Cristina¹,Jorquera Moya Manuela⁴,Oreja-Guevara Celia¹

Affiliation:

1. Neurology Department; Multiple Sclerosis Center; IdiSSC; Hospital Clinico San Carlos; Madrid Spain

2. Neurology Department; Hospital Universitario de Fuenlabrada; Madrid Spain

3. Demyelinating Disease Unit; Neurology Department; Hospital Universitario 12 de Octubre; Madrid Spain

4. Radiology Department; IdiSSC; Hospital Clinico San Carlos; Madrid Spain

Publisher

Wiley

Subject

Behavioral Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/brb3.671/fullpdf

Reference38 articles.

1. Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with Natalizumab;Beume;Journal of Clinical Neuroscience,2015

2. Treatment of relapsing remitting multiple sclerosis after 24 doses of Natalizumab: Evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP study);Clerico;JAMA Neurology,2014

3. Switching from Natalizumab to Fingolimod in multiple sclerosis: A French prospective study;Cohen;JAMA Neurology,2014

4. Natalizumab effects during a 6-month dose interruption: Relationship of pharmacokinetic (PK), pharmacodynamic (PD), and MRI measurements;Cree;Neurology,2013

5. Severe multiple sclerosis reactivation under Fingolimod 3 months after Natalizumab withdrawal;Daelman;Multiple Sclerosis Journal,2012

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrinβ-1 in disorders and cancers: molecular mechanisms and therapeutic targets;Cell Communication and Signaling;2024-01-26

2. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry;Therapeutic Advances in Neurological Disorders;2024-01

3. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12

4. Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder;Neurology;2023-07-25

5. Cytotoxic T lymphocytes in multiple sclerosis: New targets for treatment?;Translational Neuroimmunology, Volume 8;2023